State Street Corp Immunic, Inc. Transaction History

State Street Corp

$2.21 Trillion
Q1 2024

A detailed history of State Street Corp transactions in Immunic, Inc. stock. As of the latest transaction made, State Street Corp holds 130,503 shares of IMUX stock, worth $144,858. This represents 0.0% of its overall portfolio holdings.

Number of Shares

130,503

Previous 125,803 3.74%

Holding current value

$144,858

Previous $188,000 8.51%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.14 - $1.53 $5,357 - $7,191	4,700 Added 3.74%	130,503 $172,000
Q1 2023 May 15, 2023	BUY	$1.35 - $2.87 $65,610 - $139,482	48,600 Added 62.95%	125,803 $187,000
Q4 2022 Feb 14, 2023	BUY	$1.13 - $1.51 $12,768 - $17,063	11,300 Added 17.15%	77,203 $108,000
Q2 2022 Aug 15, 2022	SELL	$3.13 - $12.25 $793,993 - $3.11 Million	-253,672 Reduced 79.38%	65,903 $229,000
Q1 2022 May 16, 2022	SELL	$9.54 - $14.26 $1.38 Million - $2.06 Million	-144,425 Reduced 31.13%	319,575 $3.61 Million

Q4 2021 Feb 14, 2022	BUY	$7.34 - $10.25 $169,231 - $236,324	23,056 Added 5.23%	464,000 $4.44 Million
Q3 2021 Nov 15, 2021	BUY	$8.05 - $13.29 $721,666 - $1.19 Million	89,648 Added 25.52%	440,944 $3.9 Million
Q2 2021 Aug 16, 2021	BUY	$11.76 - $16.85 $1.2 Million - $1.72 Million	102,277 Added 41.07%	351,296 $4.31 Million
Q1 2021 May 17, 2021	BUY	$14.21 - $25.3 $2.31 Million - $4.12 Million	162,719 Added 188.55%	249,019 $3.97 Million
Q4 2020 Feb 16, 2021	BUY	$14.8 - $20.37 $231,990 - $319,299	15,675 Added 22.19%	86,300 $1.32 Million
Q3 2020 Nov 10, 2020	BUY	$11.74 - $22.0 $437,491 - $819,830	37,265 Added 111.71%	70,625 $1.31 Million
Q2 2020 Aug 14, 2020	BUY	$5.67 - $15.86 $189,151 - $529,089	33,360 New	33,360 $404,000

Others Institutions Holding IMUX

# of Institutions

Shares Held

57.6M

Call Options Held

600

Put Options Held

254K

View Full List

About IMMUNIC, INC.

Ticker IMUX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,565,000
Market Cap $33.9M
Description
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...

More about IMUX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Immunic, Inc. Transaction History